Provided by Tiger Trade Technology Pte. Ltd.

SINO BIOPHARM

5.890
+0.0701.20%
Volume:126.58M
Turnover:724.44M
Market Cap:110.50B
PE:30.79
High:5.920
Open:5.820
Low:5.420
Close:5.820
52wk High:9.120
52wk Low:3.137
Shares:18.76B
HK Float Shares:18.76B
Volume Ratio:2.52
T/O Rate:0.67%
Dividend:0.09
Dividend Rate:1.59%
EPS(LYR):0.191
ROE:12.53%
ROA:5.56%
PB:3.19
PE(LYR):30.79
PS:3.07

Loading ...

Sino Biopharmaceutical buys drugmaker Hangzhou Hygieia Biomedical for up to $172 million

Reuters
·
Jan 13

SINO BIOPHARM (01177) Appoints Lai Juan as Company Secretary and Authorized Representative

Stock News
·
Jan 13

Sino Biopharmaceutical Appoints Lai Kuen as Company Secretary and Authorised Representative

Reuters
·
Jan 13

Sino Biopharmaceutical Acquires 100% Stake in Hygieia

Reuters
·
Jan 13

Sino Biopharmaceutical - Maximum Base Consideration of RMB1.20 Bln

THOMSON REUTERS
·
Jan 13

Sino Biopharmaceutical - Acquisition of 100% Equity Interest in Hygieia

THOMSON REUTERS
·
Jan 13

SINO BIOPHARM Shares Rise Nearly 4% by Midday, Bank of America Securities Reiterates "Buy" Rating

Deep News
·
Jan 13

Hong Kong Stock Movement | SINO BIOPHARM (01177) Rises Over 4%; Management Expresses Optimism on VIIa's Inclusion in National Reimbursement Drug List; Drug Developed by Subsidiary Zhengda Tianqing

Stock News
·
Jan 13

Assessing Sino Biopharmaceutical (SEHK:1177) Valuation After Fresh IPF And Psoriasis Trial Milestones

Simply Wall St.
·
Jan 10

Sino Biopharmaceutical Stock Rallies 3.8% in Hong Kong, Outperforms Competitors

Dow Jones
·
Jan 07

Sino Biopharmaceutical Stock Climbs 2.4% in Hong Kong

Dow Jones
·
Jan 05

Sino Biopharmaceutical Stock Rallies 2.9% in Hong Kong, Outperforms Competitors

Dow Jones
·
Jan 02

Hsin Tse Spends CN¥6.4m On Sino Biopharmaceutical Stock

Simply Wall St.
·
Jan 02

Sino Biopharmaceutical Stock Slides 1.6% in Hong Kong, Underperforms Competitors

Dow Jones
·
Dec 31, 2025

Sino Biopharm (01177) Completes First Patient Enrollment in Phase III Trial for Its Self-Developed TDI01 "ROCK2 Inhibitor" for Idiopathic Pulmonary Fibrosis

Stock News
·
Dec 31, 2025

Sino Biopharm Enrolls First Patient in Phase III Trial of TDI01 for Pulmonary Fibrosis

Reuters
·
Dec 31, 2025

Sino Biopharmaceutical Stock Slides 2.0% in Hong Kong

Dow Jones
·
Dec 29, 2025

Sino Biopharmaceutical's Psoriasis Drug Meets Goal of Clinical Trial

MT Newswires Live
·
Dec 29, 2025

SINO BIOPHARM (01177): TQH3906 "TYK2/JAK1 JH2 Allosteric Inhibitor" Achieves Positive Progress in Phase II Clinical Trial for Plaque Psoriasis

Stock News
·
Dec 29, 2025

Sino Biopharmaceutical Reports Positive Phase II Results for TQH3906 in Plaque Psoriasis

Reuters
·
Dec 29, 2025